Pharmena Past Earnings Performance

Past criteria checks 0/6

Pharmena has been growing earnings at an average annual rate of 58.9%, while the Personal Products industry saw earnings growing at 3.2% annually. Revenues have been declining at an average rate of 42.9% per year.

Key information

58.9%

Earnings growth rate

59.5%

EPS growth rate

Personal Products Industry Growth36.3%
Revenue growth rate-42.9%
Return on equity-14.3%
Net Margin-546.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Think Pharmena's (WSE:PHR) Solid Earnings Are Understated

Jun 04
We Think Pharmena's (WSE:PHR) Solid Earnings Are Understated

Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong Factors

Dec 04
Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong Factors

Recent updates

We Think Pharmena's (WSE:PHR) Solid Earnings Are Understated

Jun 04
We Think Pharmena's (WSE:PHR) Solid Earnings Are Understated

Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong Factors

Dec 04
Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong Factors

Revenue & Expenses Breakdown

How Pharmena makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WSE:PHR Revenue, expenses and earnings (PLN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-230
30 Jun 2402940
31 Mar 2402940
31 Dec 2302740
30 Sep 2302650
30 Jun 230-740
31 Mar 23-3-630
31 Dec 220-540
30 Sep 225-560
30 Jun 229-380
31 Mar 2216-4120
31 Dec 2115-5120
30 Sep 2113-7130
30 Jun 2112-7130
31 Mar 2111-7120
31 Dec 2010-7120
30 Sep 2010-6120
30 Jun 2010-6130
31 Mar 2010-10180
31 Dec 1911-9180
30 Sep 1912-8170
30 Jun 1912-7150
31 Mar 1913-2100
31 Dec 1813090
30 Sep 1813090
30 Jun 1813-190
31 Mar 1814-1100
31 Dec 1712-2110
30 Sep 1714-2110
30 Jun 1716-2120
31 Mar 1716-1120
31 Dec 1616-2130
30 Sep 1616-4150
30 Jun 1616-4150
31 Mar 1616-4150
31 Dec 1517-4150
30 Sep 1517-3140
30 Jun 1515-3140
31 Mar 1514-3130
31 Dec 1414-4140
30 Sep 1413-4130
30 Jun 1414-4130
31 Mar 1415-4130

Quality Earnings: PHR is currently unprofitable.

Growing Profit Margin: PHR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PHR is unprofitable, but has reduced losses over the past 5 years at a rate of 58.9% per year.

Accelerating Growth: Unable to compare PHR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PHR is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (10.8%).


Return on Equity

High ROE: PHR has a negative Return on Equity (-14.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 01:15
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmena S.A. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Adrian KowollikDr. Kalliwoda Research
Adrian KowollikEast Value Research GmbH
Beata Szparaga-WasniewskaVestor Dom Maklerski SA